1. JCO Precis Oncol. 2022 May;6:e2100283. doi: 10.1200/PO.21.00283.

Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma 
Harboring an NTRK Oncogenic Fusion.

Thorwarth A(1), Haase K(1)(2)(3)(4)(5), Röefzaad C(1)(2)(3), Pajtler 
KW(4)(5)(6)(7), Schramm K(4)(5)(6)(7), Hauptmann K(8), Behnke A(8), Vokuhl C(9), 
Elgeti T(10), Gratopp A(11), Schulte JH(1)(4)(5), Scheer M(1), Hernáiz Driever 
P(1), Nysom K(12), Eggert A(1)(4)(5)(13), Henssen AG(1)(2)(3)(4)(5), Deubzer 
HE(1)(2)(3)(4)(5)(13).

Author information:
(1)Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin 
Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität 
Berlin, Berlin, Germany.
(2)Experimental and Clinical Research Center (ECRC) of the Charité and the 
Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 
Berlin, Germany.
(3)Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz 
Association, Berlin, Germany.
(4)German Cancer Research Center (DKFZ), Heidelberg, Germany.
(5)German Cancer Consortium (DKTK), Partner Sites Berlin and Heidelberg, 
Germany.
(6)Department of Pediatric Hematology and Oncology, University Hospital 
Heidelberg, Heidelberg, Germany.
(7)Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
(8)Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member 
of Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
(9)Section of Pediatric Pathology, Institute of Pathology, University Hospital 
Bonn, Bonn, Germany.
(10)Department of Radiology (including Pediatric Radiology), 
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin 
and Humboldt-Universität Berlin, Berlin, Germany.
(11)Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, 
Charité-Universitäts-Medizin Berlin, Corporate Member of Freie Universität 
Berlin and Humboldt-Universität Berlin, Berlin, Germany.
(12)Department of Pediatrics and Adolescent Medicine, Juliane Marie Centre, 
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
(13)Berliner Institut für Gesundheitsforschung (BIH), Berlin, Germany.

DOI: 10.1200/PO.21.00283
PMCID: PMC9200398
PMID: 35613412 [Indexed for MEDLINE]

Conflict of interest statement: Karsten NysomHonoraria: Y-mAbs 
TherapeuticsConsulting or Advisory Role: Bayer, EUSA Pharma, Y-mAbs Therapeutics 
IncTravel, Accommodations, Expenses: Bayer Anton G. HenssenResearch Funding: 
BayerNo other potential conflicts of interest were reported.